Destiny Pharma is presenting at the Bio€quity Europe conference on 17 – 19 May 2021.
If you would like to meet virtually with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is presenting at the Bio€quity Europe conference on 17 – 19 May 2021.
If you would like to meet virtually with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is presenting at the Proactive One2One Virtual Forum on 6 May 2021.
If you would like to meet virtually with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma plc
(“Destiny Pharma” or the “Company”)
Investor Presentation
Brighton, United Kingdom – 15 April 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that Neil Clark and Shaun Claydon will provide a live presentation relating to Full Year Results for year ending 31 December 2020 via the Investor Meet Company platform on 22 April 2021 at 2 pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Destiny Pharma via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma on the Investor Meet Company platform will automatically be invited.
Enquiries:
Destiny Pharma plc
+44 (0) 12 7370 4440
Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited – Nominated Adviser and Joint Broker
+44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)
WG Partners LLP – Joint Broker
+44 (0) 20 3705 9330
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communications
+44 (0) 20 3174 1789
Mary Clark / Shabnam Bashir / Manel Mateus
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infections in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the Company, please visit www.destinypharma.com
Destiny Pharma is presenting at the Pharmabiotics Conference and Partnering on 28 – 29 April 2021.
If you would like to meet virtually with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is presenting at the 2021 Digital BioInfect conference on 21 – 22 April 2021.
If you would like to meet virtually with Destiny Pharma, please email us on busdev@destinypharma.com
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Audited results for the year ended 31 December 2020
Phase 2b XF-73 clinical trial: patient recruitment completed and
positive Phase 2b data announced post year-end
£10.4M equity raise to acquire NTCD-M3 completed
Grant supported COVID-19 collaboration announced
Company funded through to Q4 2022
Brighton, United Kingdom – 14th April 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces its audited financial results for the year ended 31 December 2020.
Financial and corporate highlights
Operational highlights
Phase 2b clinical trial: XF-73 nasal gel for prevention of post-surgical infections
NTCD-M3 for prevention of C. difficile infection recurrence
SporeGen COVID-19 collaboration
Earlier pipeline and research projects
Post period highlights
Neil Clark, Chief Executive Officer of Destiny Pharma, commented:
“Destiny Pharma has delivered a very strong performance in the last 12 months and we look forward to further progress this year. We have delivered excellent Phase 2b data from our XF-73 nasal gel clinical study for the prevention of post-surgical infections and also expanded our pipeline through the acquisition of NTCD-M3 – a Phase 3 ready project targeting C. difficile gut infections. The Company has also progressed its earlier pipeline and been awarded additional grant funding including a £800,000 grant from Innovate UK to fund our COVID-19 collaboration. We closed a £10.4m equity funding in December to enable the NTCD-M3 acquisition and have a cash runway through to Q4 2022. We remain committed to developing novel products that prevent infections and have a clear clinical need and a substantial commercial opportunity”
Webcast and Conference Call
Destiny Pharma will host a webcast presentation followed by a live Q&A conference call for analysts and investors today, Wednesday 14th April 2021 at 09:30 am BST.
The webcast of the presentation will be available here and available on the Company’s website at https://www.destinypharma.com/
For details of the Q&A conference call, please contact DestinyPharma@optimumcomms.com
This announcement has been released by Shaun Claydon, CFO, on behalf of the Company.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the company, please visit https://www.destinypharma.com
Forward looking statements
Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks” “could” “targets” “assumes” “positioned” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable, but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.
The full text of the announcement may be found here.
Destiny Pharma is presenting at the 5th Future Healthcare VB100 Conference on 16 – 18 April 2021 in Suzhou, Jiangsu Province China.
If you would like to meet virtually with Destiny Pharma, please email us on busdev@destinypharma.com